March 15, 2016 8:30am EDT
Download as PDF
MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (NYSE:OPK) announces the appointment of Gregory
Henderson, M.D., Ph.D., as President of Bio-Reference Laboratories
(BRL), effective immediately. Dr. Henderson succeeds Marc Grodman, M.D.,
who is resigning, having served as Chairman, President and CEO of BRL
since founding the company in 1981. OPKO acquired BRL in August 2015.
Dr. Grodman will continue as a special advisor to OPKO and BRL to ensure
a smooth transition.
“Dr. Grodman built a billion-dollar clinical diagnostic lab company and
a strong legacy of innovating and developing new tests, all while
operating in a highly competitive environment,” said Phillip Frost,
M.D., Chairman and CEO of OPKO Health. “We are building upon Dr.
Grodman’s legacy and moving in directions that will generate a new era
of strong growth and position BRL to participate further in health and
wellness decisions. Dr. Henderson brings to BRL the ideal combination of
technical expertise and entrepreneurial and management experience. We
look forward to supporting his leadership as BRL accelerates growth from
core traditional and genetic testing services, and commercializes
important new products, such as the 4Kscore™ test for prostate cancer.”
A second-generation pathologist, Dr. Henderson founded and sold two
large regional clinical lab businesses, including NextWave Diagnostic
Laboratory in Wilmington, N.C. and Pacific Pathology Partners in
Seattle. He has been a practicing pathologist for more than 20 years and
joins BRL from the Mount Sinai Health Network, where he was the Vice
Chairman of Pathology Outreach and Affiliate Laboratory Affairs.
Commenting on his new position, Dr. Henderson said, “As part of OPKO,
Bio-Reference Laboratories is uniquely positioned to catalyze the
transformation of healthcare in the U.S. by delivering high-value,
physician-interpreted diagnostic knowledge, innovative new testing to
clinicians and patients and targeted therapeutics from our
pharmaceutical development group. Testing that provides clinical
guidance and risk stratification, minimizes invasive procedures and
bends the healthcare cost curve is the future of laboratory medicine.”
“Our 4Kscore prostate cancer risk stratification test, which has been
demonstrated in a study to reduce prostate biopsies by more than 60% and
lower attendant costs and patient risk, is the first of such tests and
is our template and roadmap,” he added. “I am looking forward to working
with the team at OPKO and BRL as we set a course to transform the
diagnostic industry and radically improve patient care.”
About Dr. Henderson
Dr. Henderson is a board-certified anatomic and clinical pathologist
with clinical expertise in breast and gynecologic diseases, and has a
nearly 20-year track record of successful founding and growth of
regional laboratories. He served as Vice Chairman and Director of
Anatomic Pathology at the Ochsner Health System in New Orleans during
Hurricane Katrina and for several years after the disaster. His most
recent role has been Vice Chairman of Pathology and Director of
Laboratory Outreach at the Mount Sinai Health Network in New York, one
of the largest hospital-based laboratory outreach programs in the U.S.
A native of New Orleans, Dr. Henderson received a B.S. in biochemistry
from Tulane University. He received his M.D. and a Ph.D. in immunology
from Vanderbilt University and was a NIH Medical Scientist Training
Program fellow. His specialty training in laboratory medicine was at the
University of Utah ARUP laboratories, and his anatomic pathology
training was at Johns Hopkins Hospital. His specialty fellowship
training in breast, gynecologic and oncologic pathology was also at
Vanderbilt University.
About OPKO Health, Inc.
OPKO Health, Inc. is a diversified healthcare company that seeks to
establish industry-leading positions in large, rapidly growing markets.
Our diagnostics business includes Bio-Reference Laboratories, the
nation's third-largest clinical laboratory with a core genetic testing
business and a 420-person sales force to drive growth and leverage new
products, including the 4Kscore® prostate cancer test and the Claros®1
in-office immunoassay platform. Our pharmaceutical business features
Rayaldee™, a treatment for SHPT in stage 3-4 CKD patients with vitamin D
insufficiency (March 29, 2016 PDUFA date) and VARUBI™ for
chemotherapy-induced nausea and vomiting (oral formulation launched by
partner TESARO, IV formulation in Phase 3). Our biologics business
includes hGH-CTP, a once-weekly human growth hormone injection (in Phase
3 and partnered with Pfizer), and a long-acting Factor VIIa drug for
hemophilia (in Phase 2a). We also have production and distribution
assets worldwide, multiple strategic investments and an active business
development strategy. More information is available at www.opko.com .
About Bio-Reference Laboratories, Inc.
Bio-Reference Laboratories is one of the largest and fastest growing
full-service diagnostic laboratories in the world, providing clinical
testing services to physician offices, clinics, hospitals, long-term
care facilities and employers while also advancing drug discovery and
development with disease foundations, academic and pharmaceutical
partners. Bio-Reference's comprehensive testing capabilities and
expertise spans molecular diagnostics, anatomical pathology, women's
health, oncology and rare disease genetics. Bio-Reference Laboratories,
and its subsidiaries, has an international presence in more than 50
countries. For more information, visit www.bioreference.com .
Forward-looking Statements
This press release contains "forward-looking statements," as that
term is defined under the Private Securities Litigation Reform Act of
1995 (PSLRA), which statements may be identified by words such as
"expects," "plans," "projects," "will," "may," "anticipates,"
"believes," "should," "intends," "estimates," and other words of similar
meaning, including statements regarding our ability to generate or
accelerate growth at Bio-Reference, our ability to transition and
transform the diagnostics industry or improve patient care through
Bio-Reference, our ability to commercialize important new products,
Bio-Reference’s or OPKO’s ability to deliver high-value or innovative
new testing to clinicians and patients, expectations regarding the
commercial success of our 4Kscore test or the ability of our 4Kscore
test to reduce prostate biopsies or reduce attendant costs and patient
risks, as well as other non-historical statements about our
expectations, beliefs or intentions regarding our business, technologies
and products, financial condition, strategies or prospects. Many factors
could cause our actual activities or results to differ materially from
the activities and results anticipated in forward-looking statements.
These factors include those described in our filings with the Securities
and Exchange Commission, as well as the risks inherent in funding,
developing and obtaining regulatory approvals of new,
commercially-viable and competitive products and treatments. In
addition, forward-looking statements may also be adversely affected by
general market factors, competitive product development, product
availability, federal and state regulations and legislation, challenges
relating to integration of Bio-Reference, including management changes,
the regulatory process for new products and indications, manufacturing
issues that may arise, patent positions and litigation, among other
factors. The forward-looking statements contained in this press release
speak only as of the date the statements were made, and we do not
undertake any obligation to update forward-looking statements. We intend
that all forward-looking statements be subject to the safe-harbor
provisions of the PSLRA.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160315005608/en/
Media
Rooney & Associates
Terry
Rooney, 212-223-0689
or
Marion
Janic, 212-223-4017
Investors
LHA
Anne
Marie Fields, 212-838-3777
or
Bruce
Voss, 310-691-7100
Source: OPKO Health, Inc.
Released March 15, 2016
email Email Alerts
location_city Company Profile
contact_page Contacts
rss_feed RSS News Feed
account_tree Sitemap
Apply on OPKO Health (Ireland)’s careers page